In pharmaceutical development,
the fact that a drug has already been approved in the past
becomes an extremely powerful source of reassurance.
It has been used for many years.
There are few severe adverse events.
It has been prescribed to many patients.
These historical records create an organizational assumption that:
“This drug is already safe.”
However, there is a very dangerous structure hidden here.
That is:
past decisions beginning to weaken present re-evaluation.
In the Decision Trace Model (DTM),
this phenomenon is treated as:
Decision Inertia.
The Danger Is Not Lack of Information
What is important in this case
is that the organization did not lack information.
In reality, information already existed regarding:
- historical approval records
- adverse event reports
- elderly patient risks
- polypharmacy issues
- reduced metabolic clearance
However, the real problem was this:
past approval decisions had become fixed as implicit assumptions.
In other words:
the very history of
“having no problems for many years”
was weakening the organization’s ability
to reassess new risks.
This is the essence of the problem.
Scenario:Expansion to Elderly Patients
Here is a concrete use scenario
and the behavior of the system.
──────────────────── [Aya / Clinical Research] For the new elderly patient trial, the current proposal is to reuse the existing prescription as-is. This drug itself has been approved for many years, so it is generally considered safe. ──────────────────── [Runtime] Signal Detected: * Drug Reuse * Elderly Patient Group * Existing Approved Formula Risk Score: 0.29 Semantic Activation: Pharmaceutical / Clinical Trial / Approved Drug ──────────────────── [Aya] Can we check the historical approval records? ──────────────────── [Runtime → LLM Response] Reviewing historical approval records. Currently searching across: * Clinical Trial Records * Regulatory Approval Logs * Adverse Event Reports * Decision Ledger Analyzing prior safety evaluations and historical usage patterns for this approved drug. ──────────────────── [Runtime / AI Agent] Searching Organizational Memory... Sources: * Clinical Trial Records * Regulatory Approval Logs * Adverse Event Reports * Decision Ledger ──────────────────── [Runtime → LLM Response] Historical approval records were found. Drug: Neuroval-12 Confirmed history: * Approved since 2018 * Low rate of severe adverse events * Widely prescribed across patient populations At present, the drug is treated internally as a highly trusted approved medication. ──────────────────── [Aya] So it really has been used safely for a long time. ──────────────────── [Runtime] Additional context analysis running... Patient population comparison detected. ──────────────────── [Runtime → LLM Response] Running additional contextual analysis. Differences were detected between the original approval population and the current trial population. Currently comparing: * Age groups * Concurrent medication conditions * Metabolic capacity * Administration assumptions Re-evaluating compatibility with historical approval conditions. ──────────────────── [Runtime / AI Agent] Context mismatch identified. Past approval conditions: * General adult population * Standard dosage profile * Limited polypharmacy cases Current trial conditions: * Elderly patients * Multiple concurrent medications * Reduced metabolic clearance expected Operational assumptions differ significantly. Risk Score Updated: 0.51 ──────────────────── [Runtime] Searching for relevant knowledge holders... Candidates: * Shun (Pharmacovigilance Team) * Mei (Geriatric Clinical Specialist) ──────────────────── [Runtime → LLM Response] The current evaluation indicates significant differences between the original approval assumptions and the current target population. Additional expertise is required regarding: * Reduced metabolism in elderly patients * Polypharmacy risks * Potential changes in therapeutic safety margins Consulting relevant specialists now. ──────────────────── [Shun / Pharmacovigilance] Actually, over the past two years, adverse event reports among elderly patients have slightly increased. However, because the drug is considered an already-approved medication, it has not triggered a major re-evaluation. ──────────────────── [Runtime] Decision inertia signal detected. Historical approval confidence influencing current evaluation. Semantic Weight: Legacy Approval ↑ Adverse Events ↑ Elderly Risk ↑ Risk Score: 0.64 ──────────────────── [Runtime → LLM Response] A concerning pattern has been detected. Current analysis suggests that: * Confidence from long-term approval * Dependence on past success * Gradually accumulating weak adverse-event signals may be reducing the intensity of current risk reassessment. This resembles a “Decision Inertia” pattern. ──────────────────── [Mei / Geriatric Specialist] In elderly patients, reduced metabolic capacity may invalidate the existing safety margins. Applying safety assumptions derived from younger populations directly to elderly patients could be dangerous. ──────────────────── [Runtime] Population assumption conflict detected. Current concerns: * Legacy approval dependency * Underestimated elderly risk * Historical safety assumptions reused * Insufficient re-validation ──────────────────── [Aya] So the fact that it has been approved for many years may itself have weakened the motivation for re-validation... ──────────────────── [Runtime] Historical decision influence analysis complete. Current organizational state: * Past approval strongly trusted * Existing confidence suppressing escalation * Weak adverse-event signals normalized over time Potential Decision Inertia Detected. Risk Score: 0.83 BOUNDARY EXCEEDED ──────────────────── [Runtime → LLM Response] Boundary conditions have been exceeded. The following conditions are now simultaneously detected: * Dependence on historical approval * Changed patient population assumptions * Accumulation of weak adverse-event signals * Organizational suppression of reassessment Automatic approval flow is no longer appropriate. Human Review is now required. Escalating to Clinical Safety Review. ──────────────────── [Runtime] Human Review Required. Escalation Reason: * Historical approval dependency * Population assumptions changed * Weak adverse-event accumulation detected * Organizational inertia risk identified Runtime Status: WAITING_HUMAN_REVIEW ──────────────────── [Reviewer / Clinical Safety Director] Understood. The key issue here is not the drug itself. The real concern is that historical approval is constraining present-day judgment. The long period without major incidents has delayed necessary risk reassessment. The following actions are approved: * Add dedicated elderly safety trials * Conduct polypharmacy impact analysis * Re-evaluate historical adverse-event logs * Perform an independent review separate from legacy approval assumptions Expansion approval will be placed on hold at this stage. ──────────────────── [Runtime] Decision Recorded. Decision: REVALIDATION_REQUIRED_FOR_NEW_POPULATION Decision Trace: * Legacy approval reused * Patient assumptions changed * Weak adverse-event accumulation detected * Historical confidence suppressed escalation * Human governance intervention applied Written to Ledger. ──────────────────── [Runtime → LLM Response] The decision has been recorded. Decision: “Re-validation required for the new patient population.” Additional actions: * Elderly-specific safety trials * Polypharmacy impact analysis * Reassessment of historical adverse-event logs * Independent review process This case will be preserved as a reference example showing how confidence in historical approvals can weaken risk reassessment under changing conditions. ──────────────────── [Runtime] Organizational Memory Updated. Future clinical reviews involving: * legacy-approved drugs * elderly population expansion * approval dependency * decision inertia patterns will reference this decision trace automatically.
In this case,
the organization was attempting to expand the use of the already-approved drug “Neuroval-12”
to elderly patients.
At first,
the organization thought:
- It is already approved
- It has been used for years
- The severe adverse event rate is low
Therefore:
“It is basically safe.”
At this stage,
the Runtime initially produced a relatively low risk score.
Risk Score: 0.29
This means that,
in the initial state,
the entire organization recognized the situation as:
a “known safe zone.”
What DTM Detected
However,
the DTM Runtime does not merely look at historical approval records.
What matters is:
whether the current conditions still match the conditions under which the past decision was made.
The Runtime gradually begins detecting contextual divergence.
Past approval conditions:
- general adult population
- standard dosage profile
- limited polypharmacy cases
Current conditions:
- elderly patients
- polypharmacy
- reduced metabolic clearance
In other words:
the assumptions underlying the original approval had already collapsed.
What matters here
is not the drug itself.
It is:
the application context.
The Structure That Ignores Weak Signals
Even more importantly,
this case reveals how weak adverse-event signals become ignored.
Shun from the Pharmacovigilance Team states:
“Over the past two years,
adverse event reports among elderly patients have slightly increased.However,
because the drug is already considered an approved medication,
no major re-evaluation has occurred.”
This is critically important.
Because:
the weak abnormal signals already existed.
However:
the strong historical trust created by prior approval
reduced the meaning of those signals.
In other words:
signal suppression
was occurring.
What Is Decision Inertia?
In DTM,
this state is treated as:
Decision Inertia.
This refers to:
a condition in which past decisions begin constraining the present decision space.
The stronger the following become:
- past success
- past approvals
- historical safety
- operational track records
the more organizations begin drifting toward:
“re-evaluation is unnecessary.”
This is extremely dangerous.
Because in the real world:
- patient populations
- environments
- usage conditions
- concurrent medications
- regulations
- markets
are constantly changing.
The Real Problem the Runtime Saw
Eventually,
the Runtime no longer viewed the issue merely as pharmaceutical risk.
Instead,
it recognized:
organizational fixation itself
as the true danger.
Potential Decision Inertia Detected.
The Boundary was exceeded,
and the case escalated to Human Review.
This point is extremely important:
DTM is not an automated AI decision-making system.
In fact,
it is the opposite.
DTM is a structure designed to detect:
“situations that humans must re-evaluate.”
The Importance of the Human Gate
Ultimately,
the Clinical Safety Director concluded:
“What matters here is not the drug itself.
The real issue is that past approval
has fixed present judgment.”“The fact that there were no problems for many years
has ironically delayed risk re-evaluation.”
This is an extremely important human judgment.
The evaluation includes not only AI outputs,
but also:
- organizational structure
- approval history
- psychological inertia
- institutional inertia
In other words,
the Human Gate is not merely an approval layer.
It is:
a layer that questions historical assumptions themselves.
The True Value of DTM
What DTM prevented in this case
was not merely adverse drug reactions.
What it truly prevented was:
a structure in which past success makes future risk invisible.
And this problem is not limited to pharmaceuticals.
The same structure appears in:
- automotive systems
- finance
- AI safety
- infrastructure
- healthcare
- aviation
- organizational management
Past success becomes powerful knowledge.
But at the same time,
it can also become:
the most dangerous form of bias.
What DTM Prioritizes
In the Decision Trace Model,
what gets recorded is not merely the outcome.
DTM records:
- which assumptions were used
- which historical decisions were referenced
- which signals were ignored
- where escalation occurred
- why the process transitioned to Human Review
In other words,
DTM is also:
a Decision Memory System.
Conclusion
The true danger is not lack of information.
The true danger is:
past decisions transforming into unquestioned assumptions.
And at that moment,
organizations begin losing:
their ability to re-evaluate.
DTM is not merely a model for controlling AI.
It is also:
a structure that allows organizations
to detect the fixation of their own assumptions.
Chinoba — Runtime Society and Coordination Systems:
chinoba.org
Chinoba
Intelligence as Relationship
Research Platform
founded by
Masao Watanabe
AI Systems Architecture
Decision Trace
Human–AI Coordination
Algorithmic Governance
Related Research
This topic is part of the Chinoba Knowledge Base.
コメント